Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings Call Transcript January 21, 2026 Johnson & Johnson reports earnings inline with ...

Johnson & Johnson (NYSE:JNJ) executives highlighted what they described as a “catapult year” in 2025, pointing to strong ...

In 2022, Pfizer became the first biopharma company to generate annual revenue of $100 billion. | Led by cancer standout ...

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

Xoma argued Janssen breached the contract Xoma had with the third-party pharmaceutical company, as well as the contract the company and Janssen had, by failing to obtain a commercial license from Xoma ...

In 2025, Google is removing reviews at unprecedented rates – and it is not accidental. Our industry analysis of 60,000 Google Business Profiles shows that deletions are being driven by a mix of: ...

Landon Murie is the CEO of Goodjuju Marketing, helping home service businesses with local SEO, stunning websites, and boosting close rates. How many Google reviews does your local business have? Does ...

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety ...

*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...

Furthermore, in prespecified analyses of subpopulations defined by prior advanced therapy treatment status, TREMFYA® demonstrated clinically meaningful results across all endpoints in both biologic ...

Customer reviews are the most influential form of local business content. Surveys routinely reveal that upwards of 90% of consumers read reviews as they search for nearby goods and services. In this ...

Johnson & Johnson (NYSE:JNJ) ranks among the top picks for a retirement portfolio. On September 26, Johnson & Johnson (NYSE:JNJ) reported that the US FDA had approved a subcutaneous induction protocol ...